MA54254A - Dérivés de benzodiazépine cytotoxique - Google Patents

Dérivés de benzodiazépine cytotoxique

Info

Publication number
MA54254A
MA54254A MA054254A MA54254A MA54254A MA 54254 A MA54254 A MA 54254A MA 054254 A MA054254 A MA 054254A MA 54254 A MA54254 A MA 54254A MA 54254 A MA54254 A MA 54254A
Authority
MA
Morocco
Prior art keywords
benzodiazepine derivatives
cytotoxic benzodiazepine
cytotoxic
derivatives
benzodiazepine
Prior art date
Application number
MA054254A
Other languages
English (en)
Inventor
Ravi V J Chari
Michael Louis Miller
Manami Shizuka
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54140691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MA54254A publication Critical patent/MA54254A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
MA054254A 2014-09-03 2015-09-02 Dérivés de benzodiazépine cytotoxique MA54254A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462045248P 2014-09-03 2014-09-03
US201462087040P 2014-12-03 2014-12-03
US201562149370P 2015-04-17 2015-04-17
US201562164305P 2015-05-20 2015-05-20

Publications (1)

Publication Number Publication Date
MA54254A true MA54254A (fr) 2021-09-22

Family

ID=54140691

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054254A MA54254A (fr) 2014-09-03 2015-09-02 Dérivés de benzodiazépine cytotoxique

Country Status (32)

Country Link
US (5) US9669102B2 (fr)
EP (2) EP3778601A1 (fr)
JP (4) JP6606545B2 (fr)
KR (2) KR102632830B1 (fr)
CN (2) CN106604927B (fr)
AU (3) AU2015311987B2 (fr)
BR (1) BR112017002963A2 (fr)
CA (1) CA2959630A1 (fr)
CL (1) CL2017000507A1 (fr)
CO (1) CO2017003011A2 (fr)
CR (1) CR20170111A (fr)
CY (1) CY1123325T1 (fr)
DK (1) DK3189056T3 (fr)
DO (1) DOP2017000053A (fr)
EA (1) EA034138B1 (fr)
EC (1) ECSP17020133A (fr)
ES (1) ES2815353T3 (fr)
HU (1) HUE051002T2 (fr)
IL (4) IL250712B (fr)
LT (1) LT3189056T (fr)
MA (1) MA54254A (fr)
MX (1) MX2017002758A (fr)
PE (1) PE20170775A1 (fr)
PH (1) PH12017500358A1 (fr)
PL (1) PL3189056T3 (fr)
PT (1) PT3189056T (fr)
RS (1) RS60751B1 (fr)
SG (2) SG10201901824UA (fr)
SI (1) SI3189056T1 (fr)
TN (1) TN2017000070A1 (fr)
TW (3) TWI757759B (fr)
WO (1) WO2016036801A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160058884A1 (en) * 2014-09-02 2016-03-03 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
RS60751B1 (sr) 2014-09-03 2020-10-30 Immunogen Inc Citotoksični derivati benzodiazepina
RU2739612C2 (ru) 2015-06-29 2020-12-28 Иммуноджен, Инк. Анти-cd123 антитела и их конъюгаты и производные
CN113004288A (zh) 2015-07-21 2021-06-22 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
WO2017136693A1 (fr) * 2016-02-05 2017-08-10 Millennium Pharmaceuticals, Inc. Conjugués anticorps-médicament ciblant la gcc
CA3044391A1 (fr) 2016-11-23 2018-05-31 Immunogen, Inc. Sulfonation selective de derives de benzodiazepine
PL3558391T3 (pl) 2016-12-23 2022-05-16 Immunogen, Inc. Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
WO2018183494A1 (fr) 2017-03-31 2018-10-04 Immunogen, Inc. Conjugués anticorps-médicament ciblant cd19
IL305224B1 (en) 2017-04-20 2024-05-01 Immunogen Inc Methods for the preparation of indolinobenzodiazepine derivatives
WO2019104289A1 (fr) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Conjugués anticorps-pyrrolobenzodiazépine
WO2019126691A1 (fr) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Conjugués anticorps-pyrrolobenzodiazépine
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
AU2020240310A1 (en) * 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
US20220168438A1 (en) * 2019-03-27 2022-06-02 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CA3154072A1 (fr) 2019-09-13 2021-03-18 Mythic Therapeutics, Inc. Constructions proteiques de liaison a l'antigene et leurs utilisations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453266A (en) 1966-03-14 1969-07-01 American Home Prod 1,2,5-benzothiadiazepine 1,1-dioxides
US3506646A (en) 1966-06-27 1970-04-14 American Home Prod Process for the preparation of 7h-pyrido (1,2-b)(1,2,5)benzothiadiazepine 5,5 - dioxides and pyrrolo(1,2-b)(1,2,5)benzothiadiazepine 5,5-dioxides
US3875162A (en) 1973-07-26 1975-04-01 Squibb & Sons Inc Certain 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 benzothiadiaza compounds
US4003905A (en) 1974-12-11 1977-01-18 E. R. Squibb & Sons, Inc. Diels-alder adducts of benzdiazepines
US4444688A (en) 1981-05-11 1984-04-24 Ciba-Geigy Corporation Imidazobenzothiadiazepines
JP2920385B2 (ja) 1988-08-18 1999-07-19 武田薬品工業株式会社 １，２，５‐ベンゾチアジアゼピン誘導体，その製造法および用途
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
WO1999006587A2 (fr) 1997-08-01 1999-02-11 Morphosys Ag Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique
US6156746A (en) 1998-08-25 2000-12-05 Bristol-Myers Squibb Company 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
AU757510C (en) 1998-08-27 2003-09-11 Medimmune Limited Pyrrolobenzodiazepines
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
CA2421447C (fr) 2000-09-08 2012-05-08 Universitat Zurich Groupes de proteines a domaines de repetition comprenant des modules de repetition
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
KR20050032110A (ko) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 신규의 효능을 갖는 탁산을 포함하는 세포독성제 및 그치료용도
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
FR2850654A1 (fr) 2003-02-03 2004-08-06 Servier Lab Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
PL1651162T3 (pl) 2003-05-20 2016-04-29 Immunogen Inc Maitansynoidy w leczeniu nowotworów
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
EP1675857B1 (fr) * 2003-10-22 2011-07-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Derives de pyrrolobenzodiazepine, compositions comprenant ces derives et methodes s'y rapportant
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
EP1773872B1 (fr) 2004-05-21 2017-03-15 The Uab Research Foundation Recepteurs de lymphocytes variables, polypeptides et acides nucleiques associes, et leurs utilisations
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
EP1817341A2 (fr) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
ATE448305T1 (de) 2005-07-08 2009-11-15 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
US7772485B2 (en) 2005-07-14 2010-08-10 Konarka Technologies, Inc. Polymers with low band gaps and high charge mobility
ITRM20050416A1 (it) 2005-08-03 2007-02-04 Uni Degli Studi Di Roma Tor Vergata Derivati delle benzodiazepine e loro usi in campo medico.
WO2007024222A1 (fr) 2005-08-22 2007-03-01 Immunogen, Inc. Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier
PL1928503T3 (pl) 2005-08-24 2012-12-31 Immunogen Inc Sposób wytwarzania koniugatów majtazynoid-przeciwciało
EP1962961B1 (fr) 2005-11-29 2013-01-09 The University Of Sydney Demi-corps : agents thérapeutiques activés par dimérisation
RS52060B (en) 2006-01-25 2012-04-30 Sanofi CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES
EP1996612A4 (fr) 2006-03-03 2010-10-20 Univ Kingston Compositions destinee au traitement des cancers
SG10201501103RA (en) 2006-05-30 2015-04-29 Genentech Inc Antibodies And Immunoconjugates And Uses Therefor
CA2655379A1 (fr) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure de l'ectodomaine du recepteur de l'insuline
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
CA2700391A1 (fr) 2007-09-24 2009-04-02 University Of Zuerich Proteines de repetition de tatou mises au point
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
CN102307896B (zh) 2008-10-31 2016-10-12 森托科尔奥索生物科技公司 基于iii型纤连蛋白结构域的支架组合物、方法及用途
NZ594177A (en) * 2009-02-05 2014-02-28 Immunogen Inc Novel benzodiazepine derivatives
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
KR101637138B1 (ko) 2010-02-24 2016-07-06 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
AR080513A1 (es) 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
EP3569256B1 (fr) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Compositions de domaine de fibronectine stabilisées, procédés et utilisations
KR20140008308A (ko) 2010-10-29 2014-01-21 이뮤노젠 아이엔씨 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트
EP2632947A4 (fr) 2010-10-29 2015-03-18 Immunogen Inc Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
MY180894A (en) 2011-04-01 2020-12-11 Immunogen Inc Methods for incresing efficacy of folr1 cancer therapy
WO2014031566A1 (fr) 2012-08-22 2014-02-27 Immunogen, Inc. Dérivés de benzodiazépine cytotoxique
CN105121421B (zh) * 2012-11-05 2020-10-02 辉瑞公司 司普力西欧他汀类似物
US10988531B2 (en) * 2014-09-03 2021-04-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
RS60751B1 (sr) * 2014-09-03 2020-10-30 Immunogen Inc Citotoksični derivati benzodiazepina

Also Published As

Publication number Publication date
US9669102B2 (en) 2017-06-06
PL3189056T3 (pl) 2020-11-02
CA2959630A1 (fr) 2016-03-10
HUE051002T2 (hu) 2021-01-28
WO2016036801A1 (fr) 2016-03-10
TWI819474B (zh) 2023-10-21
TN2017000070A1 (en) 2018-07-04
CY1123325T1 (el) 2021-12-31
JP2020075912A (ja) 2020-05-21
TWI697493B (zh) 2020-07-01
US20160082114A1 (en) 2016-03-24
KR20240023671A (ko) 2024-02-22
US20190269786A1 (en) 2019-09-05
JP2017527563A (ja) 2017-09-21
JP2022166293A (ja) 2022-11-01
TW201613929A (en) 2016-04-16
MX2017002758A (es) 2017-10-20
ES2815353T3 (es) 2021-03-29
CN106604927B (zh) 2022-08-09
CO2017003011A2 (es) 2017-07-11
IL281317B (en) 2022-04-01
JP7132311B2 (ja) 2022-09-06
SG10201901824UA (en) 2019-03-28
TW202222802A (zh) 2022-06-16
PE20170775A1 (es) 2017-07-04
AU2015311987A1 (en) 2017-03-09
ECSP17020133A (es) 2018-02-28
CN116514903A (zh) 2023-08-01
KR20170063670A (ko) 2017-06-08
DK3189056T3 (da) 2020-09-14
BR112017002963A2 (pt) 2019-07-16
US10722588B2 (en) 2020-07-28
PH12017500358A1 (en) 2017-07-17
TWI757759B (zh) 2022-03-11
IL250712B (en) 2020-04-30
US20230233697A1 (en) 2023-07-27
SG11201701455SA (en) 2017-03-30
AU2020227006A1 (en) 2020-09-24
IL291598A (en) 2022-05-01
EP3778601A1 (fr) 2021-02-17
LT3189056T (lt) 2020-09-25
AU2015311987B2 (en) 2020-06-04
EP3189056B1 (fr) 2020-06-10
KR102632830B1 (ko) 2024-02-02
CL2017000507A1 (es) 2017-11-03
AU2020227006B2 (en) 2022-05-12
IL250712A0 (en) 2017-08-31
US20170340748A1 (en) 2017-11-30
DOP2017000053A (es) 2017-05-31
RS60751B1 (sr) 2020-10-30
EA201790446A1 (ru) 2017-07-31
SI3189056T1 (sl) 2020-10-30
EP3189056A1 (fr) 2017-07-12
TW202037596A (zh) 2020-10-16
US11116845B2 (en) 2021-09-14
CR20170111A (es) 2017-05-23
JP6606545B2 (ja) 2019-11-13
IL274114A (en) 2020-06-30
AU2022202418B2 (en) 2024-06-06
AU2022202418A1 (en) 2022-05-19
PT3189056T (pt) 2020-09-04
JP2021042234A (ja) 2021-03-18
EA034138B1 (ru) 2020-01-09
CN106604927A (zh) 2017-04-26
US10238751B2 (en) 2019-03-26
US20200405870A1 (en) 2020-12-31
JP6802340B2 (ja) 2020-12-16

Similar Documents

Publication Publication Date Title
IL291598A (en) History of benzodiazepine cytotoxicity
DK3466976T3 (da) Anti-her2-antistof-lægemiddelkonjugat
DK3099692T5 (da) Bifunktionelle cytotoksiske midler
MA41898A (fr) Dérivés de quinazolinone bicyclique
CL2016002461A1 (es) Derivados macrocíclicos de pirimidina
MA39823A (fr) Dérivés de pyridine macrocyclique
DK3231803T3 (da) Dihydroindolizinonderivat
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3325483T3 (da) Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
DK3131898T3 (da) Fluoroalkylfluorenderivativer
MA41790A (fr) Dérivé de morphinane
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
GB201414116D0 (en) Benzodiazepine derivatives
MA42679A (fr) Dérivés de pyrrolidin-2-one annelés antibactériens
BR112016026725A2 (pt) Derivados de aminoéster
ES2697898T8 (es) Compuestos triazólicos tricíclicos
MA44018A (fr) Dérivés de tétrahydroisoquinoline
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
FR3025200B1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
DE112017003625A5 (de) Difluorstilben-Derivate
BR112018000209A2 (pt) derivados de oxopiridina sibstituída
PT3319956T (pt) Derivados de oxopiridina substituída
ES1154633Y (es) Cigarrillo de menta-cacao
TH1601003807A (th) คอนจูเกตของแอนติ-trop2 แอนติบอดี-ยา
DK3119744T3 (da) 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamidderivater